Multi-omic network analysis identifies dysregulated neurobiological pathways in opioid addiction

Kyle A. Sullivan¹, David Kainer¹, Matthew Lane², Mikaela Cashman^{1,3}, J. Izaak Miller¹, Michael R. Garvin¹, Alice Townsend², Bryan C. Quach⁴, Caryn Willis⁴, Peter Kruse², Nathan C. Gaddis⁴, Ravi Mathur⁴, Olivia Corradin⁵, Brion S. Maher⁶, Peter C. Scacheri⁷, Sandra Sanchez-Roige^{8,9}, Abraham A. Palmer^{8,10}, Vanessa Troiani¹¹, Elissa J. Chesler¹², Rachel L. Kember^{13,14}, Henry R. Kranzler^{13,14}, Amy C. Justice^{15,16,17}, Ke Xu^{15,18}, Bradley E. Aouizerat¹⁹, VA Million Veteran Program, Dana B. Hancock^{4*}, Eric O. Johnson^{4,20*}, and Daniel A. Jacobson^{1*}

¹Biosciences Division, Oak Ridge National Laboratory, Oak Ridge, TN

²The Bredesen Center for Interdisciplinary Research and Graduate Education, University of Tennessee-Knoxville, Knoxville, TN

³Environmental Genomics and Systems Biology Division, Lawrence Berkeley National Laboratory Berkeley, CA

⁴RTI International, Research Triangle Park, NC

⁵Whitehead Institute for Biomedical Research, Massachusetts Institute of Technology, Cambridge, MA

⁶Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD

⁷Department of Genetics and Genome Sciences, Case Western Reserve University, Cleveland, OH

⁸Department of Psychiatry, University of California San Diego, La Jolla, CA

⁹Division of Genetic Medicine, Vanderbilt University Medical Center, Nashville, TN

¹⁰Institute for Genomic Medicine, University of California San Diego, La Jolla, CA

¹¹Geisinger College of Health Sciences, Scranton, PA

¹²The Jackson Laboratory, Bar Harbor, ME

¹³Mental Illness Research, Education and Clinical Center, Crescenz Veterans Affairs Medical Center, Philadelphia, PA

¹⁴Department of Psychiatry, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
¹⁵Veterans Affairs Connecticut Healthcare System, West Haven, CT

¹⁶Department of Internal Medicine, Yale University School of Medicine, New Haven, CT

¹⁷Department of Health Policy and Management, Yale School of Public Health, New Haven, CT

¹⁸Department of Psychiatry, Yale School of Medicine, New Haven, CT

¹⁹Bluestone Center for Clinical Research, College of Dentistry, New York University, New York, NY

²⁰Fellow Program, RTI International, Research Triangle Park, NC

*Correspondence: jacobsonda@ornl.gov, ejohnson@rti.org, dhancock@rti.org

This manuscript has been authored by UT-Battelle, LLC under Contract No. DE-AC05-00OR22725 with the U.S. Department of Energy. The United States Government retains and the publisher, by accepting the article for publication, acknowledges that the United States Government retains a non-exclusive, paid-up, irrevocable, world-wide license to publish or reproduce the published form of this manuscript, or allow others to do so, for United States Government purposes. The Department of Energy will provide public access to these results of federally sponsored research in accordance with the DOE Public Access Plan (http://energy.gov/downloads/doe-public-access-plan).

1

1 Abstract

2 Opioid addiction constitutes a public health crisis in the United States and opioids cause 3 the most drug overdose deaths in Americans. Yet, opioid addiction treatments have limited 4 efficacy. To help address this problem, we used network-based machine learning techniques to 5 integrate results from genome-wide association studies (GWAS) of opioid use disorder and 6 problematic prescription opioid misuse with transcriptomic, proteomic, and epigenetic data from 7 the dorsolateral prefrontal cortex (dlPFC) in opioid overdose victims. We identified 211 highly 8 interrelated genes identified by GWAS or dysregulation in the dlPFC of individuals with opioid 9 overdose victims that implicated the Akt, BDNF, and ERK pathways, identifying 414 drugs 10 targeting 48 of these opioid addiction-associated genes. This included drugs used to treat other 11 substance use disorders and antidepressant drugs. Our synthesis of multi-omics using a systems 12 biology approach revealed key gene targets that could contribute to drug repurposing, genetics-13 informed addiction treatment, and future discovery.

14 Introduction

15

16 Worldwide, over 60 million people misuse opioid drugs resulting in an estimated 12.9 17 million healthy years of life lost (disability-adjusted life years)¹. These drugs include both opioids 18 prescribed for pain relief (e.g., hydrocodone, oxycodone) and illicit opioids (e.g., heroin, fentanyl). 19 In the United States, over 9 million people in the housed population (which excludes homeless and 20 institutionalized individuals) aged 12 and older were estimated to misuse opioids in 2020², and 21 over 80,000 people died of an opioid-related overdose in 2021 - continuing a decades long 22 epidemic of opioid misuse and overdose deaths^{3,4}. Yet only 1.27 million people in the United States 23 receive medication-assisted treatment with one of the three medications approved to treat opioid 24 use disorder (OUD)⁵: methadone (opioid agonist), buprenorphine (opioid agonist/antagonist), or 25 naltrexone (opioid antagonist). Substance use disorders are widely accepted to involve genetic and 26 experiential influences on brain circuits related to motivated behavior. Thus, there is a great need 27 for a better understanding of the neurobiology of opioid addiction and the identification of novel 28 targets for drug development.

Several recent genome-wide association studies (GWAS)⁶⁻¹⁰ have identified genetic 29 30 variants and genes associated with increased risk of opioid addiction phenotypes. Other studies 31 have identified gene dysregulation in postmortem human brains associated with opioid overdose deaths¹¹⁻¹⁵. Up to 18 genome-wide significant loci have been reported across the most recent 32 33 GWASs for OUD or prescription opioid misuse, with replicated associations being observed for OPRM1 7-10, FURIN 7-9, the SCAI/PPP6C/RABEK cluster 7-9, and PTPRF 6.9. In parallel, four 34 35 RNA-seq studies identified hundreds of potentially differentially expressed genes in human 36 postmortem dorsolateral prefrontal cortex (dlPFC), which were enriched for a variety of biological 37 functions (e.g., extracellular matrix, angiogenic cytokines, and MAPK signaling). These studies

did not include replication, but we found that 11 genes replicate across these cohorts for the dlPFC (Bonferroni corrected p < 0.05), and a meta-analysis¹⁶ of these cohorts identified up to 335 dysregulated genes in the dlPFC (Benjamini-Hochberg FDR p-value < 0.05).

41 Although these recent findings provide important clues to the biology underlying opioid 42 addiction, these genes do not function in isolation. Additional insights may be gained through a 43 systems biology approach that identifies affected functional networks from disease-associated 44 genes¹⁷. Here, we used results from existing studies to identify 404 opioid addiction-related genes 45 from which we removed potential false positives with the recently developed Gene set Refinement 46 through Interacting Networks (GRIN¹⁷) software. GRIN enabled us to identify a tightly integrated 47 set of 211 genes that mapped to multiple neurobiological pathways. Fifty of the 211 genes 48 implicated in opioid addiction signaling or other substance use disorders were tightly 49 interconnected using cross validation and a concise shortest-paths network between pairs of genes. 50 We created a conceptual model of the network mapped to BDNF and MAPK signaling pathways 51 and synaptic signaling processes, among others, showing widespread downregulation of these 52 genes in opioid addiction. Moreover, multiple genes appear to be promising targets for novel drug 53 repurposing for treating OUD based on their role as gene targets for drugs used to treat other 54 substance use disorders. Our results demonstrate the utility of integrating multiple omics in 55 systems biology approaches that leverage machine learning techniques, discovering novel 56 biological relationships that underlie opioid addiction.

57 **Results**

58 Meta-analysis of opioid addiction omics data sets combined with network biology identifies 211
59 highly interrelated genes.

60	We first identified opioid addiction-associated genes from multiple omics data sets using
61	the postmortem dlPFC and GWAS SNP-nearest gene assignment (Figure 1). Using consistent
62	significance thresholds within each omics data set across studies (Online Methods), we identified
63	404 unique opioid addiction genes from the following omics data types: 256 genes associated with
64	H3K27ac ChIP-seq peaks ¹¹ , 13 DNA methylation-associated genes ¹⁵ , 33 GWAS-associated
65	genes ⁶⁻¹⁰ , 3 protein-coding genes associated with differentially abundant proteins from LC/MS
66	proteomics ¹² , and 104 differentially expressed genes from RNA-seq ¹¹⁻¹⁴ (Supplementary Tables
67	1-7).

Of the 404 opioid addiction-related genes, we sought to identify those that are highly interconnected in biological networks using multiple lines of experimental evidence from data independent of the opioid omics data sets. Using GRIN¹⁷, we removed potential false positive genes based on network connectivity within a multiplex network consisting of 10 layers of biological evidence. GRIN uses the algorithm Random Walk with Restart (RWR) to identify tightly interconnected genes and removes those that do not depart from the gene ranks of a null distribution. GRIN identified 211 highly interrelated opioid addiction genes across omics data

75 types (Figure 2A, Supplementary Tables 8-9).

Before GRIN filtering, the 404 unfiltered genes were significantly enriched for 103 Gene Ontology (GO¹⁸) Biological Process terms. The 211 genes that remained after GRIN filtering were enriched for 293 terms, including 96 of the same enriched biological processes as were in the unfiltered gene set prior to the application of GRIN (**Figure 2B, Supplementary Tables 10-11**). In contrast, the 193 genes removed by GRIN were not significantly enriched for any GO Biological Process terms, clearly differentiating them from the 211 retained genes. Thus, the subset of 211

genes retained by GRIN were highly biologically interrelated based on interconnectivity within
the biological multiplex network and better mapping to known biological processes.

84

A subset of multi-omic genes previously implicated in opioid signaling and substance use disorders
are highly interconnected in biological networks.

Of the 211 genes retained by GRIN, we focused on a subset of 50 unique, high-confidence genes (**Supplementary Table 12**) that were either implicated across 2 or more studies or previously implicated in opioid signaling or in other substance use disorders (Online Methods). Gene set enrichment analyses indicated that, among other functions, these high confidence genes were enriched for the BDNF and MAPK signaling pathways and synaptic signaling processes

92 (Supplementary Table 13).

93 Using shortest paths network traversal to identify the fewest connections between each pair 94 of the 50 high-confidence opioid addiction genes, we found that 43 were directly connected to at 95 least one other gene in the set (Figure 3A, Supplementary Table 14). Moreover, the other 7 high 96 confidence genes were only two connections away from at least one of the other 50 high confidence 97 genes (Figure 3A, Supplementary Table 14). Only 127 additional network-connecting genes (not 98 high-confidence opioid addiction genes) were necessary to link pairs of genes that could be 99 connected as direct neighbors or by a shared neighboring gene. Furthermore, 3 of the 127 network-100 connecting genes (SERPINB1, SORCS1, and SORL1) were members of the original 211 GRIN-101 retained gene set (Figure 3A, Supplementary Table 15).

Next, we explored the interconnectivity of the 50 high-confidence opioid addiction genes
 using RWR. We employed a cross-validation approach in which a subset of the opioid addiction
 genes were used as starting points to explore the biological networks with RWR, and the remaining

105 genes were ranked against the rest of the genes in the biological network based on how often the 106 gene was visited by RWR. Using this cross-validation approach, we observed a high area under 107 receiver-operator characteristic curve (AUROC) value (AUROC = 0.94; Figure 3B). The high 108 AUROC value indicated that, during cross validation, genes that were used to explore the networks 109 frequently visited the genes that were left out of the gene set. Combined with our small shortest 110 paths network, these results confirmed that these 50 genes were highly interconnected in our 111 biological multiplex network.

112

113 Conceptual model of biological pathways underlying opioid addiction multi-omic genes.

114 After integrating the 211 multi-omic opioid addiction genes using our network approaches, 115 we identified multiple pathways unifying these genes. From this investigation, we developed a 116 conceptual model consisting of 45 opioid addiction genes and 26 other genes, proteins, or 117 molecules in associated pathways (Figure 4). Multiple genes in the BDNF pathway were 118 implicated, including BDNF, whose expression was downregulated and its receptor NTRK2 119 (TrkB), which exhibited decreased H3K27ac ChIP-seq peaks in opioid samples (Figure 4). A 120 number of genes were also implicated downstream of the BDNF pathway, including RASGRF1, 121 PIK3R1 and GSK3B in the PI3K/Akt pathway. The ERK MAPK pathway was also strongly 122 implicated, as the μ -opioid receptor (*OPRM1*), GABA_B receptor (*GABBR2*), and *PDE4B* were 123 implicated upstream of ERK along with multiple ERK phosphatases (DUSP2, DUSP4, DUSP6, 124 DUSP10, PPP6C). Downstream of the ERK and Akt pathways, CREB (CREB5) and a number of 125 its target genes were also implicated in opioid addiction, including several immediate early genes 126 (ARC, EGR1, EGR2, EGR4, FOS, MYC, NPAS4) and genes involved in synaptic plasticity (BDNF,

127 NTNI)¹⁹. Additionally, the transcription factor *RORA* was predicted to activate the transcription of 128 the multi-omic opioid addiction genes: astrotactin-2 (*ASTN2*) and galectin-3 (*LGALS3*)²⁰.

129 In addition to the BDNF, ERK, and Akt signaling pathways, multiple ion channel subunits 130 and cell adhesion molecules that may influence neurotransmission were identified by multi-omic 131 integration. Filamin A (FLNA) binds OPRM1²¹, FURIN²², and the GRIK3 subunit of the kainate 132 glutamatergic receptor²³ (Figure 4). Moreover, the astrocytic glutamate transporter EAAT2 gene 133 (SLC1A2) was implicated by hypoacetylated ChIP-seq. Multiple ionotropic GABA receptor 134 subunit genes (GABRE, GABRG3), a voltage-gated calcium channel subunit gene (CACNB2), and 135 multiple ATP or Ca²⁺-activated K⁺ channel subunit genes (ABCC8, KCNMA1, KCNN1) were 136 identified by ChIP-seq, GWAS, or RNA-seq. Genes encoding cell adhesion molecules (NCAM1 137 ²⁴, NRXN3 ²⁵) that can modulate synaptic connectivity were also implicated in our multi-omic 138 opioid addiction gene set, and microglial inflammation was implicated by the galectin-3 gene 139 (LGALS3²⁶). Notably, most genes exhibited decreased gene expression, hypoacetylated H3K27ac 140 peaks, or increased DNA methylation, except for increased GABRE and MYC gene expression and 141 increased protein abundance of LGALS3.

142

143 *Putative pharmacological target genes in opioid addiction.*

After identifying biological pathways and highly interrelated genes by integrating the multi-omic opioid addiction data sets, we identified genes whose protein products are candidates for pharmacological manipulation and potential drug repurposing. We constructed a network of 48 druggable opioid addiction genes and 414 approved or experimental drugs known to target the products of these genes (**Figure 5, Supplementary Table 16**). Currently approved treatments for opioid use disorder (OUD) or overdose that target the mu-opioid receptor (encoded by *OPRM1*)

150 are included in the network (buprenorphine, methadone, nalmefene, naloxone, and naltrexone).

151 Naltrexone is also approved for treating alcohol use disorder (AUD)²⁷, and other approved or

152 investigational AUD treatments²⁷ were also present in the network, such as a camprosate²⁷ (*GABRE*

and *GABRG3*), baclofen²⁷ (*GABBR2*), ibudilast²⁸ (*PDE4B*), and topiramate^{27,29} (*CACNB2*, *GRIK3*,

and *SCN8A*; Figure 5, Supplementary Table 16).

155 In addition to drugs approved for treating substance use disorders, multiple drugs in the 156 network targeting opioid addiction multi-omic genes are currently approved for psychiatric 157 treatment or are known to have psychiatric effects. This includes the drug spironolactone (targeting CACNB2 and PGR), which has recently been investigated for treating AUD³⁰, and multiple 158 159 approved antidepressants^{31,32} such as amitriptyline (ADRA1D, NTRK2, OPRM1), amoxapine 160 (ADRA1D, GABRE, GABRG3), and esketamine (BDNF, NTRK2). The network also includes 161 known drugs of abuse (e.g., opioids, ethanol, promethazine) and widely prescribed drugs with potential for misuse, including antipsychotics (e.g., aripriprazole^{33,34} (OPRM1), dosulepin³⁵ 162 (ADRA1D), olanzapine³³ (GABRG3), pipamperone³³ (ADRA1D), quetiapine^{33,36} (ADRA1D) and 163 164 benzodiazepines (e.g., alprazolam³⁷, lorazepam³⁸, temazepam³⁸ that all target GABRE and 165 GABRG3). A number of opioids are also present in the drug-gene target network based on their 166 characterized effects on OPRM1.

167 Furthermore, multiple ionotropic and metabotropic ion channel and receptor subunits
168 (*ADRA1D*, *CACNB2*, *GABBR2*, *GABRE*, *GABRG2*, *GRIK3*, *KCNE4*, *KCNMA1*, *KCNS3*, *NTRK2*,
169 *OPRM1*, *SCN8A*) that were identified by multi-omic integration are known targets of approved
170 drugs. Many drugs ("Other Drugs", Figure 5) targeted 2 or more of the multi-omic opioid
171 addiction genes that have not been investigated for psychiatric effects. For example, 9 genes
172 (*DAPK1*, *GSK3B*, *HIPK3*, *MARK1*, *NTRK2*, *PAK3*, *PLK4*, *STK17B*, and *STK24*) were targeted by

173 fostamatinib, indicating its potential to affect many opioid addiction genes simultaneously. 174 Furthermore, we identified antagonists and agonists for most of the gene targets present in the 175 conceptual model in **Figure 4** that were druggable, except for *FURIN* (only inhibitors), *GABBR2* 176 (only agonists), *LGALS3* (unknown action), *SLC1A2* (substrate or inhibitors), and *SST* (only 177 substrates). Thus, many of the genes in the biological pathways identified by our multi-omic 178 integration are druggable targets and are novel candidates for drug repurposing studies.

179 **Discussion**

180 In the present study, we integrated multi-omic datasets using a systems biology approach 181 to identify biological pathways and drug targets underlying opioid addiction. Importantly, by 182 integrating genome-wide association studies and omics derived from the dIPFC of individuals who 183 died from an opioid overdose, we identified distinct biological pathways implicated in this brain region, which is associated with opioid craving³⁹⁻⁴¹, such as the Akt and BDNF signaling 184 185 pathways, which were not identified in the original contributing studies. Drug-gene target network 186 integration identified candidate drugs targeting gene products implicated in opioid addiction 187 omics, as well as putative gene targets for experimental follow up. These efforts may inform the 188 development of therapeutic interventions for opioid addiction.

After identifying GWAS and omics-derived genes using consistent thresholds across opioid addiction studies, we used GRIN¹⁷ as a means of integrating these multi-omic data by identifying the most interrelated genes based on biological network connectivity. We used our previous validated multiplex network containing a dIPFC-derived predictive expression network in order to remove false positive genes from our gene set. Moreover, the dIPFC-specific network layers were congruent with the tissue of all transcriptomic and epigenetic data sets examined. Importantly, the 211 genes retained by GRIN were enriched for more GO Biological Processes

196 than the 404 genes not filtered by GRIN. From the 211 genes, we identified a subset of 50 that 197 were either previously implicated in the risk for substance use disorders, in opioid receptor 198 signaling, or by multiple opioid addiction omics. Based on the high AUROC value from our 199 random walk with restart cross-validation approach and the fact that only 127 genes were needed 200 to connect opioid addiction genes in a shortest paths network, we concluded that these 50 genes 201 were highly interconnected in our multiplex network and therefore part of the same biological 202 pathways. Notably, while some of these genes have previously been implicated in rodent models of opioid addiction (e.g., FOS⁴²⁻⁴⁴, MYC^{45,46}) or opioid receptor signaling (NTN1⁴⁷, RTP4^{48,49}), 203 204 many of the other genes are not well-characterized in relation to opioid addiction or from human 205 postmortem brain tissue.

206 Gene set enrichment analysis revealed a strong enrichment for the BDNF, ERK, and 207 Akt/PI3K pathways from our opioid addiction genes. Notably, the study describing the LC/MS 208 proteomics data set and two RNA-seq data sets previously implicated the p38 and ERK MAPK 209 pathways^{11,12}. Here, we confirm this finding and expand the implication of the ERK MAPK 210 pathway beyond the genes identified in prior studies. Animal models have shown increased ERK phosphorylation in the hippocampus⁵⁰ and of the ERK scaffold protein PEA-15⁵¹. Decreased 211 212 BDNF and associated epigenetic alterations have also been observed in the ventral tegmental area 213 of postmortem tissue from human heroin addicts⁵². Moreover, the Akt/PI3K pathway has been 214 implicated in differential gene expression from whole blood of subjects diagnosed with opioid use 215 disorder⁵³. However, to our knowledge this is the first study from the dlPFC in which multiple 216 genes in the BDNF (BDNF, NTRK2) and Akt pathways (GSK3B, PIK3R1, RASGRF1) were 217 implicated by opioid-induced transcriptomic and epigenetic alterations.

218 We also note that many of the 45 genes in our dlPFC opioid addiction conceptual model 219 affect synaptic plasticity or neuronal signaling, and were largely associated with H3K27 220 hypoacetylation and/or decreased gene expression. Both excitatory receptor subunits (CACNB2, 221 GRIK3) and inhibitory receptor subunits (ABCC8, GABBR2, GABRE, GABRG3, KCNMA1, 222 KCNN1, OPRM1) were implicated in opioid addiction, and all except the GABRE subunit were 223 associated with decreased expression or less active chromatin. Moreover, the EAAT2 glutamate 224 transporter (SLC1A2) was implicated by H3K27 hypoacetylation, an astrocytic transporter 225 responsible for removing glutamate from the synaptic cleft that has been implicated in bipolar 226 disorder and schizophrenia⁵⁴. Coupled with a net decrease in immediate early gene expression 227 (ARC, EGR1, EGR2, EGR4, ETS1, ETV5, FOS, MYC, NPAS4), genes whose expression is induced 228 by cellular activation^{55–59}, our opioid addiction genes are associated with decreased neuronal 229 activity in the dIPFC. Future studies are warranted to determine if decreased gene expression and 230 H3K27 hypoacetylation occur equally within excitatory and inhibitory neurons in the dIPFC.

231 Extending GWAS findings for opioid addiction, here we integrated omics data in the dlPFC based on its role in impulsivity and drug craving in opioid addiction^{39–41}. This brain region has 232 also been implicated in cigarette⁶⁰ and cocaine craving⁶¹. Moreover, randomized clinical trials 233 234 have been conducted using transcranial magnetic stimulation over this brain region to reduce opioid craving^{62,63}. Although omics from whole blood^{53,64,65} and other brain regions, such as the 235 midbrain⁶⁶, nucleus accumbens^{13,67}, orbitofrontal cortex⁶⁸, and striatum^{69,70} have been generated 236 237 from individuals with a history of opioid addiction, focusing on GWAS and the dIPFC enabled us 238 to examine genes from a brain region-specific perspective. Future studies should examine 239 biological pathways involving NAc omics, particularly the extent to which these pathways overlap 240 with dlPFC pathways. Furthermore, while the H3K27ac ChIP-seq data set integrated in this study

were derived from NeuN-positive neurons¹¹, omics derived from other cell types (*e.g.*, astrocytes,
 microglia, oligodendrocytes) and neuronal subtypes can inform cell type-specific epigenomic,
 transcriptomic, and proteomic changes caused by opioid addiction.

244 After identifying opioid addiction genes in the dIPFC, we sought to identify which genes 245 were known targets of previously approved medications using network visualization. Notably, approved treatments for opioid addiction⁷¹ (buprenorphine, methadone, naltrexone) or overdose 246 247 (nalmefene and naloxone) were present within our drug-gene target network. In addition to these 248 opioid-related treatments, drugs for which there is evidence of efficacy in treating alcohol use 249 disorder were present in the network, including acamprosate²⁷, baclofen²⁷, ibudilast²⁸, and 250 topiramate. Of these, topiramate has limited evidence in clinical trials for its capacity to treat opioid addiction⁷², and has been extensively assessed for treating alcohol use disorder²⁹ and to a lesser 251 252 extent cocaine⁷³ addiction. In addition to medications for treating substance use disorders, we 253 identified multiple drugs that are widely prescribed for treating psychiatric disorders that may be 254 comorbid with opioid addiction, such as depressive and anxiety disorders and schizophrenia. 255 Studies are warranted to evaluate the extent to which these drugs could be used to treat opioid 256 addiction. As many of the identified genes were associated with decreased gene expression or 257 hypoacetylated H3K72ac ChIP-seq peaks, ascertaining whether these drugs increase (agonist) or 258 decrease (antagonist) the downstream activity of these protein-coding genes is critical. 259 Furthermore, an important question for drug repurposing efforts is how opioid addiction affects 260 the expression of the genes identified in the dlPFC.

In considering drugs to be repurposed for treating addiction, weighing the potential risks associated with them is essential. A number of drugs in the network that are widely used in psychiatry, such as the benzodiazepines alprazolam³⁷ and lorazepam³⁸, have the potential for

13

misuse; thus, any efforts to repurpose these drugs must consider their potential for adverse effects.
Future work might also include using real world data to determine safety and whether there is
evidence that the use of these medications is associated with decreased use of opioids.

267 There are limitations to the current study that are worth noting. Notably, the omics from 268 the dlPFC included in the study are from bulk tissue, rather than individual cellular populations. 269 As they become available, integrating single-cell transcriptomic and epigenetic datasets would 270 give valuable insight into the neuronal and/or glial cell populations affected by opioid addiction in 271 the prefrontal cortex. Adding single cell-specific context into networks (e.g., including a 272 glutamatergic neuron-specific predictive expression network) would provide additional cellular 273 perspective into the relationships among the multi-omic genes, beyond a tissue-level perspective. 274 Furthermore, gene dysregulation in the dIPFC was identified by comparing opioid overdose death 275 cases to controls. Such differences in gene regulation may be attributable to a variety of causes 276 (e.g., chronic opioid exposure / addiction, genetic risks for opioid addiction, acute death from an 277 opioid overdose, differences in diet, other drug use, or circadian disruption). It is likely that 278 functional studies in model organisms will be needed to differentiate such causes. Finally, while 279 we have included currently available genes implicated by GWAS and omics data, there are likely 280 additional genes contributing to opioid addiction that have not yet been implicated due to these 281 genes failing to reach statistical significance. Thus, as sample sizes continue to increase from 282 opioid addiction GWAS and postmortem omics data from opioid overdose, there may be additional 283 genes and pathways implicated within the dlPFC based on increased statistical power.

In summary, we used network biology techniques to integrate multiple opioid addiction omics data sets from a systems biology perspective. By identifying biological pathways dysregulated in the dIPFC following opioid addiction and druggable gene targets in these

14

pathways, we identified candidate medications that merit experimental follow up as potentialtreatments for opioid addiction.

289 Online Methods

290

291 *Integrating opioid addiction multi-omic genes.*

Opioid addiction genes were integrated from the following types of previously published omics data sets involving postmortem dorsolateral prefrontal cortex (dlPFC) from control subjects and subjects who died of an opioid overdose: H3K27ac chromatin immunoprecipitation sequencing (ChIP-seq¹¹), DNA methylation¹⁵, liquid chromatography-mass spectrometry (LC/MS¹²), and bulk RNA sequencing (RNA-seq^{11–14}). We also included genes identified from opioid addiction genome-wide association studies (GWAS). Together, 404 unique genes present in the multiplex network were identified based on the following thresholding procedures.

299 Differential ChIP-seq peaks were derived from previous H3K27ac ChIP-seq obtained from 300 prefrontal cortex samples of controls and subjects that died of opioid overdose (Supplementary 301 **Table 1**)¹¹. From 388 differentially acetylated H3K27ac ChIP-seq peaks based on a threshold of 302 Bonferroni-corrected $p < 1e^{-7}$, peaks were re-mapped to genes using the "annotatePeak" function 303 from the ChIPseeker R function⁷⁴ using hg19/GRCh37 coordinates and a 1kb window around the 304 transcriptional start site to define the promoter region. This annotation was used in contrast to the GREAT⁷⁵ peak-to-gene annotation listed in the original publication¹¹, as ChIP-seeker annotates 305 306 the location of peaks (i.e. intronal, exonal, promoter, 5'UTR, 3'UTR, distal intergenic) and 307 mapped peaks to genes that GREAT did not annotate. Reciprocally, if ChIPseeker did not map a 308 peak to a gene, the GREAT peak-to-gene annotation was used. Together, these 388 H3K27ac 309 ChIP-seq peaks mapped to 267 unique genes. Furthermore, we included the 5 genes (ASTN2,

310	DUSP4, ENOX1, GABBR2, KCNMA1) associated with variant enhancer loci lost in opioid
311	overdose subjects using promoter-capture Hi-C that were statistically significant at FDR-corrected
312	$p < 1e^{-6}$, which added 2 unique genes to the H3K27ac ChIP-seq-associated gene list. Thirteen non-
313	coding RNAs identified by ChIP-seq peaks were excluded from downstream analysis as they were
314	not present in any layer of the multiplex network (Supplementary Table 7): MIR30D, MIR3201,
315	MIR3914-1, MIR4262, MIR4264, MIR4319, MIR4432, MIR4480, MIR4689, MIR4714, MIR4790,
316	MIR488, and SNORA72. In total, 256 unique genes were included among the H3K27ac ChIP-seq

317 peaks.

Differentially methylated genes were identified using a previously published epigenomewide association study of dlPFC tissue from subjects who died from opioid overdose using the Illumina Infinium MethylationEPIC BeadChip DNA methylation chip testing 850,000 CpG regions (**Supplementary Table 2**)¹⁵. Thirteen CpG sites were identified with adjusted *p*-values of 0.4 (uncorrected $p < 6e^{-6}$) and 3 CpG islands that were not mapped to genes (cg25084741, cg10759972, and cg26506680) were excluded. This yielded 13 unique genes identified by opioidinduced differential DNA methylation that were present in the multiplex network.

Genes were included from opioid use disorder⁸⁻¹⁰ and prescription opioid misuse⁶ GWAS 325 based on SNP-nearest gene associations from SNPs with $p < 5e^{-8}$, resulting in 19 unique GWAS 326 327 genes; an additional 15 unique genes were also identified from multi-trait analysis of GWAS 328 (MTAG) using European opioid use disorder GWAS, alcohol use disorder, and cannabis use 329 disorder summary statistics (Supplementary Table 3)⁷. These opioid addiction GWAS yielded 330 34 unique genes, but one gene (TMX2-CTNND1) was not present in any layer of the multiplex 331 and was excluded from downstream analyses (33 unique GWAS genes; Supplementary Tables 332 **6-7**).

Differentially abundant proteins (**Supplementary Table 4**) were identified from a previously published LC/MS proteomics study from postmortem dIPFC from control and subjects diagnosed with opioid use disorder¹². Three protein coding genes (*ATP5J2*, *LGALS3*, *TAF15*) were included based on a threshold of adjusted *p*-value < 0.05 and absolute value of log₂ fold change (FC) greater than or equal to 1.5 (log₂FC \leq -1.5 or log₂FC \geq 1.5) which were included in downstream analyses.

Differentially expressed genes (DEGs; **Supplementary Table 5**) were identified from four RNA-seq studies derived from postmortem dlPFC of controls and subjects who died of opioid overdose or were diagnosed with opioid use disorder^{11–14}. DEGs were included in downstream analyses based on thresholds of adjusted *p*-value < 0.05 and $|log_2FC \ge 0.5|$. Using these thresholds, we identified 106 unique genes identified in opioid addiction by RNA-seq and 103 genes present in the multiplex were included in downstream analyses (*AC018647.3*, *AL606753.2*, and *PARTICL* were excluded, **Supplementary Table 7**).

Multiple genes were implicated in opioid addiction by multiple lines of biological evidence. Four genes were identified across multiple omics data types: *DUSP4*, *DUSP6*, *ETV5*, and *PLA2GS*. Additionally, 60 ChIP-seq opioid addiction genes were identified by multiple H3K27ac ChIP-seq peaks, and *ARL4D* was identified as a DEG in two separate RNA-seq studies^{12,13}. Furthermore, *FURIN*^{7–9}, *NCAM1*^{7,8}, *OPRM1*^{7–10}, and the *SCAI/PPP6C/RABEPK*^{7–9} gene cluster were identified across multiple opioid addiction GWAS.

352

353 *Multiplex network generation.*

354 Multiplex gene-gene networks were assembled from 10 layers from different types of 355 biological evidence using GENCODE IDs for all genes. None of the multiplex network data

356 sources were from any of the opioid addiction omics data sets. The following network layers were 357 used from HumanNet (version 2.0²³): co-citation, co-essentiality, co-expression, pathway 358 databases, gene neighborhood, interologs, and phylogenetic associations. A merged protein-359 protein interaction network was created by merging networks from HumanNet (version 2.0, 360 literature curated and high-throughput assay-derived connections) and high-confidence 361 interactions from STRING (version 11.0, taxa = 9606, protein.actions.v11.0, mode=binding, min 362 score = 700^{76}). Transcription factor-target relationships specific to the prefrontal cortex were 363 included from Pearl et al²⁰. All edge (connection) weights were normalized on a 0 to 1 scale 364 irrespective of line of biological evidence.

Brain region-specific network layers were also incorporated using RNA-seq data from the Genotype-Tissue Expression (GTEx) consortium⁷⁷ and explainable-AI algorithms applied on the Summit supercomputer at the Oak Ridge Leadership Computing Facility (OLCF). Using iterative random forest leave-one-out prediction (iRF-LOOP⁷⁸), gene-gene predictive networks were made from the prefrontal cortex (BA9) given that all omics were derived from this brain region. After computing all edges with iRF-LOOP, only high-confidence edges (edge weights > 0.05) were included in the multiplex network.

After compiling all network layers, the 10-layer multiplex was assembled using the "RWR_make_multiplex" function within the RWRtoolkit R library⁷⁹. The final multiplex network contained 51,183 unique genes and 3,419,975 unique edges.

375

376 Filtering opioid addiction multi-omic genes using GRIN

We applied GRIN (Geneset Refinement using Interacting Networks)¹⁷ to identify the most
 biologically interrelated opioid addiction genes and remove potential false positive genes. GRIN

379 was applied with the previously validated 10-layer multiplex network described above using the 380 404 unique genes identified from multiple omics data using equal weights for all genes. GRIN 381 retained 211 opioid addiction genes which were used in all subsequent analyses. Gene set 382 enrichment for Gene Ontology (GO) Biological Processes was then tested on the 404 genes prior 383 to GRIN as well as the GRIN retained and GRIN removed gene sets using ToppGene⁸⁰. Gene set 384 enrichments were considered significant at a threshold of FDR-corrected *p*-value < 0.05.

385 After retaining 211 opioid addiction genes, a set of 50 high-confidence genes were 386 identified using two criteria. Three genes that were present in multiple omics data sets and retained 387 by GRIN were included: DUSP4, DUSP6, and ETV5. Next, a subset of the 211 genes was included 388 if each gene were associated with opioid-mediated signaling or a substance use disorder based on 389 previously published research. This resulted in 47 additional genes in the high-confidence gene set 390 based on a literature search from PubMed (https://pubmed.gov) using the following search terms: 391 "[gene] opioid", "[gene] addiction", "[gene] substance use disorder." ToppGene was then used to 392 test for gene set enrichment of GO Biological Processes, GO Cellular Components, GO Molecular 393 Functions, biological pathway enrichment (includes KEGG⁸¹, Reactome⁸², and PANTHER⁸³ 394 pathways), and transcription factor binding sites (MSigDB⁸⁴).

395

396 Shortest paths network

A shortest paths network connecting all pairs of the 50 opioid addiction-associated genes was generated using the shortest paths algorithm using the R package RWRtoolkit⁷⁹. The 10-layer multiplex network was merged into a single network layer, and using the shortest paths algorithm identified the shortest possible network connections among all 2500 possible gene-gene pairs. Genes who were direct neighbors with at least one other opioid addiction gene (43 out of 50 opioid

addiction genes) were imported into the program Cytoscape⁸⁵ (Version 3.9.1, Cytoscape
Consortium, San Diego, CA, USA) for network visualization. For the other 7 genes (*ADRA1D*, *FURIN, KIAA0040, LGALS3, NTN1, SLC1A2, SST*), the connections between these genes and
other opioid addiction genes that were separated by one neighbor ("network-connecting genes")
were included in the Cytoscape visualization.

407

408 *Random walk with restart cross validation.*

409 Using the RWR-CV function within RWRtoolkit⁷⁹, we tested the interconnectivity of our 410 refined 50 opioid addiction gene set using random walk with restart (RWR) with 5-fold cross 411 validation. In one cross validation fold, 10 genes were left out of our input gene set, and the other 412 40 genes were used as seed genes for RWR. All genes in the multiplex network were ranked by 413 RWR, with true positives counted as left-out genes that were ranked by RWR, and true negatives 414 counted as other genes in the network. A receiver-operator characteristic (ROC) curve was 415 calculated based on true positive rate (true positives / true positives + false negatives) and false 416 positive rate (false positives / false positives + true negatives), which was plotted using the R 417 package ggplot2⁸⁶. The area under the curve was computed using RWRtoolkit.

418

419 Overview and conceptual model visualizations

420 An overview diagram of the approach used in this study was constructed using 421 Biorender.com. Similarly, the conceptual model illustrating biological pathways among opioid 422 addiction genes was constructed using Biorender.com.

423

424 *Identifying druggable targets involved in opioid addiction.*

425 Multi-omic opioid addiction genes were then cross-referenced with previously 426 demonstrated gene-drug interactions. Using DrugBank⁸⁷, a network of drug-gene target 427 interactions was created using all 211 genes retained by GRIN. These drug interactions included 428 FDA-approved, investigational, and experimental uses of drugs targeting these genes, resulting in 429 48 gene targets and 414 total drugs. Drug-gene target interactions were visualized using Cytoscape.

430 Data Availability

431 No primary data was generated for the present study. All primary data from DNA 432 methylation, GWAS summary statistics, H3K27ac ChIP-seq, LC/MS proteomics, and RNA-seq 433 are from previously published manuscripts. GWAS summary statistics from the Million Veteran 434 Program (Kember et al., 2022) are available on the NIH database of Genotypes and Phenotypes 435 (dbGaP) under accession phs001672. GWAS summary statistics from Deak et al., 2022 are 436 publicly available at https://medicine.yale.edu/lab/gelernter/stats/. GWAS summary statistics 437 from Gaddis et al., 2022 are available under dbGaP under accession phs000454.v1.p1.We used 438 the top 10,000 SNPs from Sanchez-Roige et al., 2021 GWAS summary statistics, which are 439 publicly available at 440 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8562028/bin/41380 2021 1335 MOESM2 ES 441 M.xlsx. Previously published data from H3K27ac ChIP-seq is available under dbGaP accession 442 number phs002724.v1.p1. Previously published DNA methylation data is available at GEO 443 accession number GSE164822. Previously published LC/MS proteomics is available at the 444 ProteomeXchange PRIDE repository under PXD025269. Previously published RNA-seq data 445 sets are available under dbGaP accession phs002724.v1.p1, GEO accession numbers 446 GSE221515 and GSE174409, and SRA accession number SUB9455518.

21

447	All activities were approved by the Oak Ridge National Laboratory Institutional Review
448	Board. The demographics of subjects from which GWAS summary statistics were derived along
449	with descriptions of Institutional Review Boards to approve these studies have been
450	characterized in previous publications and all subjects provided informed consent. All
451	postmortem brain tissue samples are exempt from human subjects research.
452	

453 Code Availability

The GRIN software and multiplex network that was used is publicly available at github.com/sullivanka/GRIN. Publicly available R packages (ggplot2, tidyverse) were used for data analysis and visualization using R version 4.1.3, and ChIP-seq peaks were assigned using ChIPseeker (version 1.30.3). Additional code used to generate results are available upon request.

458 Ac

Acknowledgements/Funding Sources

459 This manuscript has been authored by UT-Battelle, LLC under Contract No. DE-AC05-460 00OR22725 with the U.S. Department of Energy. The United States Government retains and the 461 publisher, by accepting the article for publication, acknowledges that the United States 462 Government retains a non-exclusive, paid-up, irrevocable, world-wide license to publish or 463 reproduce the published form of this manuscript, or allow others to do so, for United States 464 Government purposes. The Department of Energy will provide public access to these results of 465 sponsored research in accordance with the DOE Public Access federally Plan 466 (http://energy.gov/downloads/doe-public-access-plan). This research used resources of the Oak 467 Ridge Leadership Computing Facility, which is a DOE Office of Science User Facility supported

468	under Contract DE-AC05-00OR22725. This work was funded by NIH grants DA051908 (EOJ,
469	DAJ), DA051913 (DBH, DAJ), and DA054071 (NCG, OC, BSM, SS, AP, VT, EC, EOJ, DAJ)
470	and VA grant I01 BX004820 (ACJ, HRK) and the Veterans Integrated Service Network Mental
471	Illness Research, Education and Clinical Center (HRK). This research is based on data from the
472	Million Veteran Program, Office of Research and Development, Veterans Health Administration,
473	and was supported by award # I01 BX004820. This publication does not represent the views of
474	the Department of Veteran Affairs or the United States Government.
475	

476 Author Contributions

477 Conceptualization: DBH, EOJ, DAJ; Methodology: KAS; Software: KAS, DK, ML, MC, JIM;

478 Formal analysis: KAS; Investigation: EOJ; Writing - Original Draft: KAS, EOJ; Writing - Review

479 & Editing: KAS, MRG, AT, BCQ, CW, NCG, RM, OC, BSM, PCS, SS, AP, VT, EJC, RLK,

480 HRK, ACJ, KX, BEA, DBH, EOJ, DAJ; Supervision: DBH, EOJ, DAJ; Funding acquisition:
481 HRK, ACJ, DBH, EOJ, DAJ.

482 **Competing Interests**

483 HRK is a member of advisory boards for Dicerna Pharmaceuticals, Sophrosyne Pharmaceuticals, 484 Enthion Pharmaceuticals, and Clearmind Medicine; a consultant to Sobrera Pharmaceuticals; the 485 recipient of research funding and medication supplies from Alkermes for an investigator-initiated 486 study; a member of the American Society of Clinical Psychopharmacology's Alcohol Clinical 487 Trials Initiative, which was supported in the last three years by Alkermes, Dicerna, Ethypharm, 488 Lundbeck, Mitsubishi, and Otsuka; and is named as an inventor on PCT patent application

- 489 #15/878,640 entitled: "Genotype-guided dosing of opioid agonists," filed January 24, 2018. The
- 490 other authors have no disclosures to make.



493 Figure 1. Multi-omic integration of opioid addiction phenotypes.

494 Beginning with multiple data sets collected from opioid addiction (OA) cases and controls, OA 495 genes were assembled from H3K27ac chromatin immunoprecipitation (ChIP-seq; peaks assigned 496 to nearest gene), DNA methylation (CpG methylation site to nearest gene), genome-wide 497 association studies (GWAS; SNP-to-gene assignment), differentially abundant proteins by LC/MS 498 proteomics (protein-coding genes), and differential gene expression by RNA-seq. After integrating 499 the overlapping and distinct genes identified by each omics data type, a biological multiplex 500 network consisting of networks from multiple lines of biological evidence were constructed using 501 data sources separate from any of the opioid addiction omics data sets. Network traversal 502 algorithms were used to identify mechanistic connections among the multi-omic genes and identify 503 dysregulated pathways in the dorsolateral prefrontal cortex (dlPFC). Figure made with 504 Biorender.com.



506 Figure 2. Opioid addiction genes are retained by GRIN from multiple omics types 507 and result in more Gene Ontology enrichments compared to the unfiltered gene set.

508 a. Percentages of genes retained (orange) or removed (blue) by GRIN by each omics type, 509 including genes shared across omics types (ChIP-seq RNAseq, GWAS MTAG GWAS, pcHiC-510 VELs ChIPseq, and pcHiC-VELs ChIPseq RNAseq). b. From the 404 original opioid addiction 511 genes (Pre-GRIN), 159 GO Biological Process terms were significantly enriched. The 211 genes 512 retained by GRIN (Post-GRIN) were enriched for 96 of the same GO Biological Processes but 513 were uniquely enriched for 197 additional terms. Only 7 terms were significantly enriched in the 514 set of 404 genes prior to GRIN that were not significantly enriched in the post-GRIN set of 211 515 genes.



517 Figure 3. Multi-omic opioid addiction genes are tightly interconnected as 518 demonstrated by network biology.

a. Network visualization of the shortest pathways between all pairs of 50 opioid addiction (OA)associated genes from GWAS and dlPFC omics. 43 genes were directly connected to at least one other gene by the networks (Direct Neighbor OA genes), and only 127 additional genes (Network-Connecting Genes) were necessary to connect the other 7 genes (One Neighbor OA Genes) from

523 10 network layers. Notably, three Network-Connecting genes (SERPINB1, SORCS1, and SORL1)

524 were members of the larger 211 GRIN-retained opioid addiction gene set. Gene Legend: indicates

525 gene color from which omics data type or if it is a Network-Connecting Gene; Network

526 Connections legend indicates network layer used to connect gene pairs. b. Using Random Walk

527 with Restart to explore the biological networks starting from 50 OA-associated genes, 5-fold cross

validation exhibits high recall based upon a mean area under receiver-operator characteristic curve

529 (AUROC) value of 0.94.

medRxiv preprint doi: https://doi.org/10.1101/2024.01.04.24300831; this version posted January 4, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.



531 Figure 4. Conceptual model of opioid addiction pathways implicated by multi-omic 532 integration.

533 Conceptual model of 45 opioid addiction genes identified via multiple omics data types and 26 534 additional genes, proteins, or molecules in associated pathways. The mu-opioid receptor (OPRM1) 535 and GABBR2 receptor inhibit downstream adenylyl cyclase/protein kinase A (PKA) signaling. 536 PKA can phosphorylate ERK1 which is bound by the scaffolding protein PEA-15, and ERK can 537 also be activated by upstream netrin (NTN1) and BDNF signaling molecules that were implicated 538 in opioid addiction (BDNF, NTRK2, RASGRF1). DUSP2, DUSP4, DUSP6, DUSP10, and PPP6C 539 all function as ERK phosphatases and PDE4B can reduce PKA activation, while Akt signaling 540 (implicated by PIK3RA and GSK3B) and ERK signaling can activate NPAS4 and CREB5 to 541 activate transcription of NTN1 (identified by DNA hypermethylation) and synaptic plasticity and immediate early genes (ARC, BDNF, EGR1, EGR2, EGR4, ETS1, ETV5, FOS, MYC, NPAS4, SST). 542 543 ERK can also activate the transcription factor RORA to promote transcription of ASTN2 and 544 galectin-3 (LGALS3), which is important in microglial inflammatory processes. OPRM1 545 (chaperoned to the cell membrane by RTP4) and FURIN share a common scaffolding protein 546 (filamin A; FLNA) with the glutamatergic kainate receptor subunit GRIK3, and SLC1A2 is an 547 important glutamate transporter in astrocytes. Additional potassium and calcium channel subunits 548 (ABCC8, KCNMA1, KCNN1) were implicated along with multiple ionotropic GABA_A receptor 549 subunits (GABRE, GABRG3) and cell adhesion molecules (NCAM1 and NRXN3). Color of gene 550 text indicates which opioid addiction omics data set the gene originated from, and shading of the gene indicates the logFC of expression or histone acetylation state (not applicable for pc Hi-C 551 552 VELs or GWAS genes). NTN1 was hypermethylated by a mean difference of 0.29 rather than a 553 logFC difference in methylation state. Gray text genes indicate genes or molecules involved in 554 pathways but were not implicated by an omics study.



555 Figure 5. Drug-gene target network includes current opioid treatments and putative 556 candidate drugs for treatment repurposing.

557 A network of 414 drugs and 48 target genes (orange) implicated in multi-omic opioid addiction studies. Current opioid addiction/opioid use disorder (OUD) treatments (light yellow-green) 558 559 targeting the µ-opioid receptor (OPRM1) include buprenorphine, methadone, and naltrexone, as well as nalmefene and naloxone to prevent overdose. In addition to nalmefene and naltrexone 560 561 which is used to treat OUD and alcohol use disorder (AUD), four approved or experimental alcohol 562 use disorder treatments (light green) were present in the network: acamprosate (targeting GABRE 563 and GABRG3), baclofen (targeting GABBR2), ibudilast (targeting PDE4B), and topiramate 564 (CACNB2, GRIK3, and SCN8A). Drugs with known psychiatric effects (teal) targeting opioid 565 addiction genes include spironolactone (also investigated for AUD), antidepressants (e.g., 566 amitriptyline, amoxipine, and esketamine, targeting 6 unique genes). Some drugs in the network 567 with known misuse potential (dark blue) include antipsychotic drugs (e.g., aripriprazole, 568 quetiapine) and many benzodiazepines that act as anxiolytics (e.g., alprazolam, lorazepam). 569 Multiple ion channel receptor subunits (15 total) are also known drug targets, and 9 genes are 570 known to be targeted by fostamatinib. Other drugs with yet unknown psychiatric effects targeting 571 opioid addiction genes are shown in light blue, along with a number of opioids (gray). This druggene target network may guide additional hypotheses and follow up experiments to test the 572 573 efficacy of these drugs in combating opioid addiction processes.

574 **References**

- 575 1. Unodc. World drug report 2021-drug market trends: cannabis & opioids. (2021).
- 576 2. Substance Abuse and Mental Health Services Administration. Key substance use and mental
- 577 health indicators in the United States: Results from the 2020 national survey on drug use and
- 578 health. (*HHS Publication No. PEP21-07-01-003, NSDUH Series H-56*). (2021).
- 579 3. Spencer, M., Miniño, A. & Warner, M. Drug overdose deaths in the United States, 2001-
- 580 2021. https://stacks.cdc.gov/view/cdc/122556 (2022) doi:10.15620/cdc:122556.
- 581 4. Ahmad FB, Cisewski JA, Rossen LM, Sutton P. Provisional drug overdose death counts.
- 582 *National Center for Health Statistics.* (2023).
- 583 5. U.S. Department of Health and Human Services. HHS By The Numbers: Combating the
 584 Opioids Crisis. (2019).
- 585 6. Sanchez-Roige, S. et al. Genome-wide association study of problematic opioid prescription
- use in 132,113 23andMe research participants of European ancestry. *Mol. Psychiatry* **26**,
- 587 6209–6217 (2021).
- 588 7. Deak, J. D. et al. Genome-wide association study in individuals of European and African
- ancestry and multi-trait analysis of opioid use disorder identifies 19 independent genome-
- 590 wide significant risk loci. *Mol. Psychiatry* (2022) doi:10.1038/s41380-022-01709-1.
- 591 8. Kember, R. L. et al. Cross-ancestry meta-analysis of opioid use disorder uncovers novel loci
- 592 with predominant effects in brain regions associated with addiction. *Nat. Neurosci.* (2022)
- 593 doi:10.1038/s41593-022-01160-z.
- 594 9. Gaddis, N. *et al.* Multi-trait genome-wide association study of opioid addiction: OPRM1
 595 and beyond. *Sci. Rep.* 12, 16873 (2022).
- 596 10. Zhou, H. et al. Association of OPRM1 Functional Coding Variant with Opioid Use
- 597 Disorder: A Genome-Wide Association Study. *JAMA Psychiatry* 77, 1072–1080 (2020).

- 598 11. Corradin, O. *et al.* Convergence of case-specific epigenetic alterations identify a confluence
- 599 of genetic vulnerabilities tied to opioid overdose. *Mol. Psychiatry* **27**, 2158–2170 (2022).
- 600 12. Mendez, E. F. et al. Angiogenic gene networks are dysregulated in opioid use disorder:
- 601 evidence from multi-omics and imaging of postmortem human brain. *Mol. Psychiatry*
- 602 (2021) doi:10.1038/s41380-021-01259-y.
- 603 13. Seney, M. L. et al. Transcriptional Alterations in Dorsolateral Prefrontal Cortex and Nucleus
- Accumbens Implicate Neuroinflammation and Synaptic Remodeling in Opioid Use
 Disorder. *Biol. Psychiatry* 90, 550–562 (2021).
- 606 14. Sosnowski, D. W. et al. Differential expression of NPAS4 in the dorsolateral prefrontal
- 607 cortex following opioid overdose. Drug and Alcohol Dependence Reports **3**, 100040 (2022).
- 5. Shu, C. *et al.* Epigenome-wide study of brain DNA methylation following acute opioid
 intoxication. *Drug Alcohol Depend.* 221, 1–7 (2021).
- 610 16. Carter, J. Quach, B., Willis, C., Hancock, D., Montalvo-Ortiz, J., Logan, R., Walss-Bass, C.,
- 611 Maher, B., Johnson, E., PGC-SUD Epigenetics Working Group. Identifying novel gene
- 612 dysregulation associated with opioid overdose death: A meta-analysis of differential gene
- 613 expression in human prefrontal cortex; Poster Presentation: PB1478. American Society of
- Human Genetics, Los Angeles, CA, Oct 2022.
- 615 17. Sullivan, K. A. *et al.* Digging deeper into GWAS signal using GRIN implicates additional
- 616 genes contributing to suicidal behavior. bioRxiv (2022) doi:10.1101/2022.04.20.22273895.
- 617 18. Harris, M. A. et al. The Gene Ontology (GO) database and informatics resource. Nucleic
- 618 Acids Res. **32**, D258–61 (2004).
- 619 19. Funahashi, Y. et al. Phosphorylation of Npas4 by MAPK Regulates Reward-Related Gene
- 620 Expression and Behaviors. *Cell Rep.* **29**, 3235–3252.e9 (2019).

- 20. Pearl, J. R. *et al.* Genome-Scale Transcriptional Regulatory Network Models of Psychiatric
 and Neurodegenerative Disorders. *Cell Systems* 8, 122–135.e7 (2019).
- 623 21. Onoprishvili, I. et al. Interaction between the mu opioid receptor and filamin A is involved
- 624 in receptor regulation and trafficking. *Mol. Pharmacol.* **64**, 1092–1100 (2003).
- 625 22. Liu, G. et al. Cytoskeletal protein ABP-280 directs the intracellular trafficking of furin and
- 626 modulates proprotein processing in the endocytic pathway. J. Cell Biol. 139, 1719–1733
- 627 (1997).
- 628 23. Hwang, S. *et al.* HumanNet v2: human gene networks for disease research. *Nucleic Acids*629 *Res.* 47, D573–D580 (2019).
- 630 24. Schachner, M. Neural recognition molecules and synaptic plasticity. *Curr. Opin. Cell Biol.*631 9, 627–634 (1997).
- 632 25. Dai, J., Liakath-Ali, K., Golf, S. R. & Südhof, T. C. Distinct neurexin-cerebellin complexes

633 control AMPA- and NMDA-receptor responses in a circuit-dependent manner. *Elife* 11,
634 (2022).

- 635 26. Liu, Y. *et al.* Galectin-3 regulates microglial activation and promotes inflammation through
 636 TLR4/MyD88/NF-kB in experimental autoimmune uveitis. *Clin. Immunol.* 236, 108939
 637 (2022).
- 638 27. Carpenter, J. E., LaPrad, D., Dayo, Y., DeGrote, S. & Williamson, K. An Overview of
- 639 Pharmacotherapy Options for Alcohol Use Disorder. *Fed. Pract.* **35**, 48–58 (2018).
- 640 28. Grodin, E. N. et al. Ibudilast, a neuroimmune modulator, reduces heavy drinking and
- 641 alcohol cue-elicited neural activation: a randomized trial. *Transl. Psychiatry* **11**, 355 (2021).
- 642 29. Kranzler, H. R. et al. Post-treatment effects of topiramate on alcohol-related outcomes: A
- 643 combined analysis of two placebo-controlled trials. *Addict. Biol.* **27**, e13130 (2022).

644	30. Farokhnia, M. et al. Spironolactone as a potential new pharmacotherapy for alcohol use
645	disorder: convergent evidence from rodent and human studies. Mol. Psychiatry 27, 4642-
646	4652 (2022).

647 31. Jha, M. K. et al. Intranasal esketamine effectively treats treatment-resistant depression in

adults regardless of baseline irritability. J. Affect. Disord. **321**, 153–160 (2023).

- 649 32. Kishi, T. et al. Antidepressants for the treatment of adults with major depressive disorder in
- 650 the maintenance phase: a systematic review and network meta-analysis. *Mol. Psychiatry*
- 651 (2022) doi:10.1038/s41380-022-01824-z.
- 652 33. Merino, D. et al. Antipsychotic Abuse, Dependence, and Withdrawal in the Pediatric
- 653 Population: A Real-World Disproportionality Analysis. *Biomedicines* **10**, (2022).
- 654 34. Ferreira, R. C. M. *et al.* Peripheral Antinociception Induced by Aripiprazole Is Mediated by
 655 the Opioid System. *Biomed Res. Int.* 2017, 8109205 (2017).
- 656 35. Dorman, A., Talbot, D., Byrne, P. & O'Connor, J. Misuse of dothiepin. *BMJ* 311, 1502
 657 (1995).
- 658 36. Klein, L., Bangh, S. & Cole, J. B. Intentional Recreational Abuse of Quetiapine Compared
- to Other Second-generation Antipsychotics. *West. J. Emerg. Med.* **18**, 243–250 (2017).
- 660 37. Ait-Daoud, N., Hamby, A. S., Sharma, S. & Blevins, D. A Review of Alprazolam Use,
- 661 Misuse, and Withdrawal. J. Addict. Med. 12, 4–10 (2018).
- 38. Garretty, D. J., Wolff, K., Hay, A. W. & Raistrick, D. Benzodiazepine misuse by drug
 addicts. *Ann. Clin. Biochem.* 34 (Pt 1), 68–73 (1997).
- 664 39. Liu, S. *et al.* Brain responses to drug cues predict craving changes in abstinent heroin users:
 665 A preliminary study. *Neuroimage* 237, 118169 (2021).
- 40. Wang, L. et al. Altered brain intrinsic functional hubs and connectivity associated with

- 667 relapse risk in heroin dependents undergoing methadone maintenance treatment: A resting-
- state fMRI study. *Drug Alcohol Depend.* **219**, 108503 (2021).
- 669 41. Huhn, A. S. et al. Prefrontal cortex response to drug cues, craving, and current depressive
- 670 symptoms are associated with treatment outcomes in methadone-maintained patients.
- 671 *Neuropsychopharmacology* **44**, 826–833 (2019).
- 42. Doherty, J. M., Cooke, B. M. & Frantz, K. J. A role for the prefrontal cortex in heroin-
- 673 seeking after forced abstinence by adult male rats but not adolescents.
- 674 *Neuropsychopharmacology* **38**, 446–454 (2013).
- 43. Kuntz, K. L., Patel, K. M., Grigson, P. S., Freeman, W. M. & Vrana, K. E. Heroin self-
- administration: II. CNS gene expression following withdrawal and cue-induced drugseeking behavior. *Pharmacol. Biochem. Behav.* **90**, 349–356 (2008).
- 678 44. Koya, E. *et al.* Enhanced cortical and accumbal molecular reactivity associated with
- 679 conditioned heroin, but not sucrose-seeking behaviour. J. Neurochem. 98, 905–915 (2006).
- 680 45. Flaisher-Grinberg, S., Persaud, S. D., Loh, H. H. & Wei, L.-N. Stress-induced epigenetic
- 681 regulation of κ-opioid receptor gene involves transcription factor c-Myc. *Proc. Natl. Acad.*
- 682 *Sci. U. S. A.* **109**, 9167–9172 (2012).
- 46. Park, S. W., Li, J., Loh, H. H. & Wei, L.-N. A novel signaling pathway of nitric oxide on
- transcriptional regulation of mouse kappa opioid receptor gene. J. Neurosci. 22, 7941–7947
 (2002).
- 47. Tsai, N.-P., Bi, J., Loh, H. H. & Wei, L.-N. Netrin-1 signaling regulates de novo protein
- 687 synthesis of kappa opioid receptor by facilitating polysomal partition of its mRNA. J.
- 688 *Neurosci.* **26**, 9743–9749 (2006).
- 48. Décaillot, F. M., Rozenfeld, R., Gupta, A. & Devi, L. A. Cell surface targeting of mu-delta

- 690 opioid receptor heterodimers by RTP4. *Proc. Natl. Acad. Sci. U. S. A.* 105, 16045–16050
 691 (2008).
- 692 49. Fujita, W. et al. Regulation of an Opioid Receptor Chaperone Protein, RTP4, by Morphine.
- 693 *Mol. Pharmacol.* **95**, 11–19 (2019).
- 694 50. Bagherpasand, N. et al. Effect of topiramate on morphine-induced conditioned place
- 695 preference (Cpp) in rats: Role of erk and creb proteins in hippocampus and cerebral cortex.

696 Iranian Journal of Pharmaceutical Research 18, 2000–2010 (2019).

- 697 51. Ramos-Miguel, A., Esteban, S. & García-Sevilla, J. A. The time course of unconditioned
- 698 morphine-induced psychomotor sensitization mirrors the phosphorylation of FADD and
- 699 MEK/ERK in rat striatum: role of PEA-15 as a FADD-ERK binding partner in striatal

700 plasticity. *Eur. Neuropsychopharmacol.* **20**, 49–64 (2010).

- 52. Koo, J. W. *et al.* Epigenetic basis of opiate suppression of Bdnf gene expression in the
 ventral tegmental area. *Nat. Neurosci.* 18, 415–422 (2015).
- 53. Dai, Q. et al. Whole Transcriptome Sequencing of Peripheral Blood Shows That
- 704 Immunity/GnRH/PI3K-Akt Pathways Are Associated With Opioid Use Disorder. Front.

705 *Psychiatry* **13**, 893303 (2022).

70654. Fiorentino, A., Sharp, S. I. & McQuillin, A. Association of rare variation in the glutamate

receptor gene SLC1A2 with susceptibility to bipolar disorder and schizophrenia. *Eur. J.*

- 708 *Hum. Genet.* **23**, 1200–1206 (2015).
- 55. O'Donnell, A., Odrowaz, Z. & Sharrocks, A. D. Immediate-early gene activation by the
- 710 MAPK pathways: what do and don't we know? *Biochem. Soc. Trans.* **40**, 58–66 (2012).
- 711 56. Heroux, N. A. et al. Differential expression of the immediate early genes c-Fos, Arc, Egr-1,
- and Npas4 during long-term memory formation in the context preexposure facilitation effect

- 713 (CPFE). Neurobiol. Learn. Mem. 147, 128–138 (2018).
- 57. Gerhauser, I., Alldinger, S., Ulrich, R. & Baumgärtner, W. Spatio-temporal expression of
- 715 immediate early genes in the central nervous system of SJL/J mice. Int. J. Dev. Neurosci.
- **23**, 637–649 (2005).
- 717 58. Tran, D. D. H. et al. Transcriptional regulation of immediate-early gene response by
- 718 THOC5, a member of mRNA export complex, contributes to the M-CSF-induced
- 719 macrophage differentiation. *Cell Death Dis.* **4**, e879–e879 (2013).
- 59. Gao, P., Limpens, J. H. W., Spijker, S., Vanderschuren, L. J. M. J. & Voorn, P. Stable
- immediate early gene expression patterns in medial prefrontal cortex and striatum after long-
- term cocaine self-administration. *Addict. Biol.* **22**, 354–368 (2017).
- 723 60. Hayashi, T., Ko, J. H., Strafella, A. P. & Dagher, A. Dorsolateral prefrontal and
- 724 orbitofrontal cortex interactions during self-control of cigarette craving. *Proc. Natl. Acad.*
- 725 *Sci. U. S. A.* **110**, 4422–4427 (2013).
- 726 61. Huhn, A. S. et al. Increased neural activity in the right dorsolateral prefrontal cortex during
- a risky decision-making task is associated with cocaine use in methadone-maintained
- 728 patients. Drug Alcohol Depend. 205, 107650 (2019).
- 62. Eskandari, Z. et al. A sham-controlled clinical trial to examine the effect of bilateral tDCS
- on craving, TNF- α and IL-6 expression levels, and impulsivity of males with opioid use
- 731 disorder. J. Addict. Dis. **39**, 347–356 (2021).
- 732 63. Tsai, T.-Y. et al. Add-on repetitive transcranial magnetic stimulation in patients with opioid
- use disorder undergoing methadone maintenance therapy. *Am. J. Drug Alcohol Abuse* 47,
 330–343 (2021).
- 735 64. Cabrera-Mendoza, B. et al. Within subject cross-tissue analyzes of epigenetic clocks in

- substance use disorder postmortem brain and blood. *Am. J. Med. Genet. B Neuropsychiatr. Genet.* (2022) doi:10.1002/ajmg.b.32920.
- 738 65. Montalvo-Ortiz, J. L., Cheng, Z., Kranzler, H. R., Zhang, H. & Gelernter, J. Genomewide
- 739 Study of Epigenetic Biomarkers of Opioid Dependence in European-American Women.
- 740 Sci. Rep. 9, 4660 (2019).
- 741 66. Saad, M. H. et al. Differentially expressed gene networks, biomarkers, long noncoding
- RNAs, and shared responses with cocaine identified in the midbrains of human opioid
 abusers. *Sci. Rep.* 9, 1534 (2019).
- 744 67. Albertson, D. N., Schmidt, C. J., Kapatos, G. & Bannon, M. J. Distinctive profiles of gene
- expression in the human nucleus accumbens associated with cocaine and heroin abuse.

746 *Neuropsychopharmacology* **31**, 2304–2312 (2006).

- 747 68. Kozlenkov, A. et al. DNA Methylation Profiling of Human Prefrontal Cortex Neurons in
- 748 Heroin Users Shows Significant Difference between Genomic Contexts of Hyper- and

Hypomethylation and a Younger Epigenetic Age. *Genes* **8**, (2017).

- 750 69. Egervari, G. *et al.* Chromatin accessibility mapping of the striatum identifies tyrosine kinase
- FYN as a therapeutic target for heroin use disorder. *Nat. Commun.* **11**, 4634 (2020).
- 752 70. Egervari, G. et al. Striatal H3K27 Acetylation Linked to Glutamatergic Gene Dysregulation
- in Human Heroin Abusers Holds Promise as Therapeutic Target. *Biol. Psychiatry* 81, 585–
 594 (2017).
- 755 71. Coffa, D. & Snyder, H. Opioid Use Disorder: Medical Treatment Options. Am. Fam.
- 756 *Physician* **100**, 416–425 (2019).
- 757 72. Zullino, D. F. *et al.* Topiramate in opiate withdrawal- comparison with clonidine and with
- carbamazepine/mianserin. Subst. Abus. 25, 27–33 (2004).

- 759 73. Rush, C. R. *et al.* Topiramate-phentermine combinations reduce cocaine self-administration
 760 in humans. *Drug Alcohol Depend.* 218, 108413 (2021).
- 761 74. Yu, G., Wang, L.-G. & He, Q.-Y. ChIPseeker: an R/Bioconductor package for ChIP peak
- annotation, comparison and visualization. *Bioinformatics* **31**, 2382–2383 (2015).
- 763 75. McLean, C. Y. et al. GREAT improves functional interpretation of cis-regulatory regions.
- 764 *Nat. Biotechnol.* **28**, 495–501 (2010).
- 765 76. Szklarczyk, D. et al. STRING v11: protein-protein association networks with increased
- coverage, supporting functional discovery in genome-wide experimental datasets. *Nucleic*
- 767 *Acids Res.* **47**, D607–D613 (2019).
- 768 77. Melé, M. *et al.* The human transcriptome across tissues and individuals. *Science* 348, 660–
 769 665 (2015).
- 770 78. Cliff, A. et al. A High-Performance Computing Implementation of Iterative Random Forest

for the Creation of Predictive Expression Networks. *Genes* **10**, (2019).

- 772 79. Kainer, D., Lane, M., Sullivan, K., Cashman, M. & Miller, J. dkainer/RWRtoolkit. (Oak
- 773 Ridge National Laboratory (ORNL), Oak Ridge, TN (United States), 2022).
- 774 doi:10.11578/DC.20220607.1.
- 775 80. Chen, J., Bardes, E. E., Aronow, B. J. & Jegga, A. G. ToppGene Suite for gene list

enrichment analysis and candidate gene prioritization. *Nucleic Acids Res.* 37, W305–11
(2009).

- 81. Ogata, H., Goto, S., Fujibuchi, W. & Kanehisa, M. Computation with the KEGG pathway
 database. *Biosystems.* 47, 119–128 (1998).
- 780 82. Gillespie, M. *et al.* The reactome pathway knowledgebase 2022. *Nucleic Acids Res.* 50,
 781 D687–D692 (2022).

- 782 83. Mi, H. & Thomas, P. PANTHER pathway: an ontology-based pathway database coupled
- 783 with data analysis tools. *Methods Mol. Biol.* **563**, 123–140 (2009).
- 84. Liberzon, A. et al. Molecular signatures database (MSigDB) 3.0. Bioinformatics 27, 1739–
- 785 1740 (2011).
- 786 85. Shannon, P. et al. Cytoscape: a software environment for integrated models of biomolecular
- 787 interaction networks. *Genome Res.* **13**, 2498–2504 (2003).
- 788 86. Wickham, H. ggplot2: elegant graphics for data analysis Springer-Verlag New York; 2009.
- 789 Preprint at (2016).
- 790 87. Wishart, D. S. *et al.* DrugBank 5.0: a major update to the DrugBank database for 2018.
- 791 *Nucleic Acids Res.* **46**, D1074–D1082 (2018).